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Abstract
Background: Psoriasin (S100A7) expression has previously been associated with psoriasiform
hyperplasia as well as with tumor progression in breast cancer. Its expression profile for different
stages of skin lesions is unknown. The aim of this study was to determine the relationship between
psoriasin (S100A7) and tumor progression in skin.
Methods: Psoriasin was assessed by immunohistochemistry and levels of expression determined
by semi-quantitative scoring in skin biopsies from 50 patients. The cohort included normal skin,
actinic keratosis, squamous carcinoma in-situ, invasive squamous cell carcinoma, and basal cell
carcinoma.
Results: In normal skin, psoriasin was rarely detected in epidermis but was expressed in underlying
adnexae. In abnormal epidermis psoriasin was frequently expressed in abnormal keratinocytes in
actinic keratosis, in-situ and invasive squamous cell carcinoma, but was rarely observed in the basal
epidermal layer or in superficial or invasive basal cell carcinoma. The highest levels of expression
were seen within squamous carcinoma in-situ. Significantly reduced levels of expression were
observed in both unmatched (p = 0.0001) and matched (p < 0.004) invasive squamous cell
carcinoma. Psoriasin expression within abnormal squamous lesions correlated with mitotic count
(r = 0.54, p = 0.0036), however no significant relation was found with the intensity of dermal
inflammatory cell infiltrates assessed within each pathology.
Conclusion: These results suggest that altered psoriasin expression occurs in abnormal epidermis
and that downregulation may be related to the onset of invasion in squamous cell carcinoma in skin.
Background
Psoriasin (S100A7) is a member of the S100 gene family
[1] and was first identified as a 11.4 kDa secreted protein
expressed in skin involved by psoriasis [2]. It was subse-
quently shown that psoriasin expression is also present in
other inflammatory skin conditions [3] and that psoriasin
can exert a chemotactic influence on inflammatory cells
[4], suggesting that it may play a general role in this aspect
of inflammatory skin diseases. However, its pattern of ex-
pression in skin is also associated with altered keratinoc-
yte differentiation [5,6], and psoriasin has been found to
be expressed in squamous cell carcinomas of bladder [7,8]
and in breast carcinoma [9,10]. In the latter, increasing ex-
pression parallels early stages of tumorigenesis and pso-
riasin is highly expressed in ductal carcinoma in-situ, but
psoriasin is often downregulated in adjacent invasive car-
cinoma [10]. Psoriasin is thus also associated with altered
and abnormal pathways of epithelial cell differentiation.
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In the present study we have examined psoriasin expres-
sion in dysplastic, pre-invasive and invasive skin lesions
to determine the relative importance of the relationship
with inflammation and tumor progression in the skin.
Methods
Study Cohort
The study cohort was selected from the archives of the De-
partment of Pathology, Heath Sciences Center, Winnipeg
Canada, from skin surgical biopsies and resections. In
each of 5 categories, half the cases were selected to show
either minimal or prominent inflammatory infiltrates
within the dermis. The cohort comprised paraffin tissue
blocks from 50 patients in the following categories: nor-
mal skin (n = 10), dysplastic actinic keratosis (10), squa-
mous cell carcinoma in situ (10), and mixed in-situ and
invasive squamous cell carcinoma (10), and basal cell car-
cinoma (10). The latter category also included 2 superfi-
cial and 8 invasive types. Mitotic count was assessed in 3
representative high power fields within squamous lesions.
Psoriatic skin lesions (x3) were also stained as positive
controls.
Immunohistochemistry
Immunohistochemical staining (IHC) for psoriasin was
performed essentially as previously described [11], but us-
ing an automated tissue immunostainer (Ventana Medi-
cal Systems, Phoenix, AZ, U.S.A.). The specificity of the
primary antibody (concentration 1: 3000) has been previ-
ously described [11]. Psoriasin expression was assessed by
light microscopy. Expression levels (Psoriasin IHC score)
were determined by semi-quantitative scoring derived
from estimation of the product of the intensity of psoria-
sin expression and the relative proportion of positive epi-
thelial cells within the entire specimen and lesion when
present [11]. Statistical analysis was performed with Prism
Graphpad software and using Mann Whitney test and Wil-
coxon rank sum tests as appropriate.
Results
Psoriasin expression was absent in normal epidermis,
however there was occasional staining seen in normal ad-
nexal structures and there was high expression seen in all
psoriatic lesions stained as positive controls (Fig. 1). Pso-
riasin expression was prominent in most dysplastic and
neoplastic epidermal lesions (Fig. 2) and also in hyper-
plastic benign epithelium at the border of some lesions.
Strong cytoplasmic and nuclear staining was seen as pre-
viously described [12] within the superficial epidermis
but was absent from the stratum basalis. Staining was also
occasionally noted within stromal elements of the dermis
adjacent to regions of high epithelial cell expression, but
not in more distant areas.
The level of psoriasin expression was determined by semi-
quantitative scoring and assessed in relation to lesion type
(Fig. 3A). In squamous cell lesions, psoriasin was ex-
pressed at moderate levels in actinic keratosis, at signifi-
cantly higher levels in all cases of carcinoma in-situ (Fig.
2C), and at significantly lower levels within the invasive
component in all cases of invasive squamous cell carcino-
ma (Fig. 2E). Psoriasin expression was observed in only
one case of basal cell carcinoma and was limited to re-
gions of apparent squamous cell differentiation. There
was no significant difference in the level of psoriasin ex-
pression within in-situ carcinoma occurring alone or
within in-situ carcinoma components associated with ad-
jacent invasive carcinoma. The difference in levels ob-
served between unmatched cases of in-situ and invasive
carcinoma was also evident when in-situ carcinoma was
compared to adjacent invasive components within the
same case (Fig. 2E). Downregulation of psoriasin within
the invasive component was observed within 9/10 cases
(Fig. 3B).
Figure 1
Immunohistochemical detection of psoriasin in nor-
mal and psoriatic skin Pattern of psoriasin expression in 
normal skin and psoriatic lesions detected by immunohisto-
chemistry. Psoriasin is absent from normal dermis, epidermis 
(A, double arrow), and eccrine glands (A & D, single arrow) 
but is expressed in hair follicles and occasional associated 
sebaceous glands (A & C, asterix). Psoriasin is highly 
expressed in superficial layers of epidermis within psoriatic 
lesions (B). Original magnification A&B 200×, C&D 400×.BMC Dermatology 2003, 3 http://www.biomedcentral.com/1471-5945/3/1
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Psoriasin expression correlated with mitotic rate in squa-
mous epithelium and lesions but not in basal cell carcino-
mas. The mitotic rate in squamous epithelium assessed in
all 'categories' (normal, actinic keratosis, in-situ and inva-
sive squamous carcinomas) showed a strong correlation
with psoriasin expression (r = 0.73, p < 0.0001) and this
relationship persisted when normal skin was excluded
and analysis was restricted only to squamous pathologies
(r = 0.54, p = 0.0036, Fig. 4A). There was no statistically
significant difference in psoriasin expression with and
without marked inflammation, either within each pathol-
ogy category or between all lesions combined (Fig. 4B).
Discussion
The S100 genes encode small proteins that share EF-hand
helix-loop-helix domains that are important for their
function as calcium binding proteins [1] and many
potential biological roles [1]. Altered expression of several
S100s has also been implicated in cancer progression [13–
17]. Psoriasin (S100A7) was initially identified as a
protein highly expressed in abnormally differentiating ke-
ratinocytes derived from psoriatic skin [2]. It was subse-
quently identified as a gene overexpressed in squamous
cell carcinoma of the bladder [7] and in primary invasive
breast tumors [9]. We and others [10,18]. have also
shown that psoriasin expression is low in normal breast
epithelium, increased in pre-invasive preinvasive ductal
carcinoma in-situ and that it can be downregulated in ad-
jacent invasive components [10].
In contrast to several other S100 proteins [19], psoriasin
expression is restricted to the epithelial component in
those tissues where it has been studied, such as skin,
breast, and bladder [3,7,11,20]. In epidermis, psoriasin is
expressed infrequently and at low levels in normal epithe-
lial cells, but can be highly induced in keratinocytes under
specific pathological circumstances. These include hyper-
plasia associated with inflammatory skin lesions and dys-
plasia associated with neoplastic progression. A recent
SAGE analysis identified psoriasin amongst a small subset
of genes highly and consistently overexpressed in actinic
keratosis compared to normal skin [21]. Several of these
genes, including psoriasin, are located in the 'epithelial
differentiation complex' region on chromosome 1q21
[22]. Our results here show that psoriasin is not expressed
by either normal or abnormal basal cells (in superficial
basal cell carcinoma), indicating a specific association
with squamous cell differentiation. However, while fac-
tors related to cellular differentiation clearly comprise an
important aspect of the regulation of psoriasin [6], the
downregulation that is frequently seen in squamous and
breast ductal carcinoma cells within invasive compared to
in-situ components [10], suggests regulation by addition-
al factors that may also be associated with the invasive
process. Dedifferentiation may also be an integral step in
Figure 2
Immunohistochemical detection of psoriasin in skin 
Pattern of psoriasin expression in pre-neoplastic and neo-
plastic skin lesions detected by immunohistochemistry (pan-
els A,C,E,F) with corresponding areas from H&E stains 
(panels B,D,F,H). Psoriasin is moderately (A, right) or highly 
(C) expressed in carcinoma in-situ alone and carcinoma in-
situ associated with invasive carcinoma (E, upper), and down-
regulated in invasive squamous carcinoma (E, lower). Psoria-
sin is absent in invasive basal cell carcinoma (G, upper) in 
comparison with adjacent positively staining normal hair folli-
cles (G, lower right). Original magnification, 200×.BMC Dermatology 2003, 3 http://www.biomedcentral.com/1471-5945/3/1
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Figure 3
Psoriasin expression relative to lesion type Panel A: distribution of expression within cases with normal skin (N), actinic 
keratosis (AK), squamous carcinoma in-situ (IS), invasive squamous cell carcinoma (INV), and basal cell carcinoma (BCC). Bars 
represent medians. All p values were determined by Mann Whitney test. Panel B: comparison of expression within individual 
cases between areas of squamous carcinoma in-situ (IS) and invasive squamous cell carcinoma (INV). The p value was deter-
mined by Wilcoxon Rank Sum test.BMC Dermatology 2003, 3 http://www.biomedcentral.com/1471-5945/3/1
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Figure 4
Psoriasin expression relative to mitosis and inflammation within lesion type. Panel A: Psoriasin expression levels 
determined by IHC score relative to mitotic count in squamous epithelial pathologies (actinic keratosis, squamous carcinoma 
in-situ and squamous invasive lesions). Panel B: Psoriasin expression levels determined by IHC score relative to inflammation 
within each lesion type. Distribution of expression within cases without inflammation (-) and with inflammation (+) for actinic 
keratosis (AK-, AK+), squamous carcinoma in-situ (IS-, IS+), and invasive squamous cell carcinoma (INV-, INV+). Bars repre-
sent medians. P values determined by Mann Whitney test.BMC Dermatology 2003, 3 http://www.biomedcentral.com/1471-5945/3/1
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the invasive process [23]. Several specific factors have
been implicated in the regulation of psoriasin, including
retinoic acid which is intimately involved in the control of
squamous cell differentiation [24]. Psoriasin is also regu-
lated by calcium, UV irradiation, and altered cell adhesion
in the skin [11,24–28] and stress related factors such as
growth factor deprivation, confluency, and loss of adhe-
sion in breast epithelial cells  [9,18]. Examination of the
promotor confirms an important role for regulation by
the AP-1 transcription factor complex [29], consistent
with the known role of c-jun and JNK activation in the cel-
lular response to UV stress [30]. Activation of the AP-1
pathway is also known to be important in skin tumorigen-
esis, progression and invasion [31].
The biological function of psoriasin remains to be fully
understood. The association with psoriasis [2] other in-
flammatory skin diseases [3] and both in-vitro [4] and in-
vivo [24] studies in skin and breast [11] suggest a role as a
secreted chemotactic factor. However, in the current
study, no significant relation was found with the intensity
of dermal inflammatory cell infiltrates. It is possible that
the marked changes in psoriasin expression that are ap-
parent with cellular differentiation and progression, ob-
scured a relationship with inflammation within the small
subgroups of each category of pathology. It is also possi-
ble that psoriasin has less influence on inflammatory re-
sponses in neoplastic as opposed to inflammatory skin
disease or that other cofactors are present and necessary
for this action in inflammatory skin pathologies.
Psoriasin may also have other functions within epithelial
cells. It is apparent that while psoriasin is secreted it can
also be localized within keratinocytes and breast cells
[12], in common with other S100 proteins [32]. Interac-
tions with intracellular fatty acid binding proteins and
transglumatinases [12,33]. have also been reported and
possible intracellular functions that have been proposed
include roles in either altered differentiation [6], resist-
ance to apoptosis [18], or tumor invasion [10].
The possibility that psoriasin might provide a clinical
marker for pathological diagnosis has previously been
considered. Psoriasin may be a useful indicator of squa-
mous differentiation for tumor subclassification, and
while this may have little practical clinical significance in
the management of skin tumors, in some systems such as
uterine and bladder tumors this may have prognostic sig-
nificance [7,8]. The potential role as a predictive factor for
progression in pre-invasive squamous and breast lesions
remains to be determined.
Conclusions
These results show that psoriasin expression is altered in
association with early stages of skin tumorigenesis with
highest levels of expression within preinvasive squamous
cell carcinoma in-situ and downregulation in invasive dis-
ease. A possible functional role in mediating invasion re-
mains to be explored.
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